Mantle Cell Lymphoma (MCL) Recruiting Phase 2 Trials for Ibrutinib (DB09053)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03478514Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaTreatment
NCT03710772Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT03617484Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell LymphomaTreatment
NCT01880567Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT02682641Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLTreatment
NCT02471391ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)Treatment